Galectin-3 Serum Levels Could Help Clinicians Screen for Salivary Gland Tumor Patients

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Mar 28

PMID 29580041

Citations 3

Authors

Azadeh Andisheh-Tadbir

Maryam Mardani

Mahyar Malekzadeh

Tayebe Amirbeigi Tafti

Bijan Khademi

Affiliations

Soon will be listed here.

Abstract

Objective: To identify serum levels of galectin-3 in salivary gland cancer and healthy populations; a prospective analysis was performed on serum specimens from 105 patients with salivary gland cancer and 56 healthy persons. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure levels of galectin-3 (GAL-3). Serum levels were compared between patients with salivary gland tumors and healthy control. A total of 105 patients were enrolled in the study (55 men, 50 women). Result: Mean age was 45.5 years. Thirty-nine patients with malignant and 66 cases with benign tumors were compared with 56 healthy participants with a mean age of 51.7. No statistically significant differences were observed when comparing GAL-3 serum levels between malignant and benign salivary gland tumor patients, but a statistically significant difference was found between case and control patients with p-values of 0.02. Serum levels of galectin-3 protein were elevated in patients with salivary gland cancer compared with the healthy population. Conclusion: The difference between benign and malignant tumor patients was significant, but revealed no clinic pathological characteristics in malignant tumors. To the best of the authors’ knowledge, this is the first time a study suggests that GAL-3 serum levels could help clinicians screen for salivary gland cancer.

Citing Articles

A critical influence of HIF-1 on MMP-9 and Galectin-3 in oral lichen planus.

Hazzaa H, El Shiekh M, Elkashty O, Magdy E, Riad D, Khalifa E BMC Oral Health. 2024; 24(1):756.

PMID: 38951854 PMC: 11218350. DOI: 10.1186/s12903-024-04457-6.

Revisiting Multi-Omics Data to Unravel Galectins as Prognostic Factors in Head and Neck Squamous Cell Carcinoma.

Barros O, DAgostino V, Santos L, Ferreira R, Vitorino R Biomedicines. 2024; 12(3).

PMID: 38540141 PMC: 10968280. DOI: 10.3390/biomedicines12030529.

The Protective Effect of miR-27-3p on Ischemia-Reperfusion-Induced Myocardial Injury Depends on HIF-1α and Galectin-3.

Song Z, Zhong X, Ning Z, Song X J Cardiovasc Transl Res. 2022; 15(4):772-785.

PMID: 35194735 DOI: 10.1007/s12265-021-10203-y.

References

DHaene N, Sauvage S, Maris C, Adanja I, Mercier M, Decaestecker C . VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis. PLoS One. 2013; 8(6):e67029. PMC: 3684579. DOI: 10.1371/journal.pone.0067029. View

Takenaka Y, Fukumori T, Raz A . Galectin-3 and metastasis. Glycoconj J. 2004; 19(7-9):543-9. DOI: 10.1023/B:GLYC.0000014084.01324.15. View

Xie L, Ni W, Chen X, Xiao M, Chen B, He S . The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 2012; 138(6):1035-43. DOI: 10.1007/s00432-012-1178-2. View

Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D . Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013; 4(4):542-9. PMC: 3720602. DOI: 10.18632/oncotarget.923. View

Isic T, Savin S, Cvejic D, Marecko I, Tatic S, Havelka M . Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol. 2010; 136(12):1805-12. DOI: 10.1007/s00432-010-0838-3. View

Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama H . Serum level of galectin-3 in human bladder cancer. J Med Invest. 2008; 55(1-2):127-32. DOI: 10.2152/jmi.55.127. View

Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T . Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today. 2012; 43(8):901-5. DOI: 10.1007/s00595-012-0378-3. View

Barondes S, Cooper D, Gitt M, Leffler H . Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994; 269(33):20807-10. View

Nangia-Makker P, Nakahara S, Hogan V, Raz A . Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr. 2007; 39(1):79-84. PMC: 3616377. DOI: 10.1007/s10863-006-9063-9. View

10.

Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S . Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep. 2002; 9(6):1307-12. View

11.

Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y . Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol. 1999; 15(1):143-8. DOI: 10.3892/ijo.15.1.143. View

12.

Schoeppner H, Raz A, Ho S, Bresalier R . Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer. 1995; 75(12):2818-26. DOI: 10.1002/1097-0142(19950615)75:12<2818::aid-cncr2820751206>3.0.co;2-#. View

13.

Vereecken P, Boudjeltia K, DEBRAY C, Awada A, Legssyer I, Sales F . High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol. 2005; 31(1):105-9. DOI: 10.1111/j.1365-2230.2005.01992.x. View

14.

Hughes R . Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1999; 1473(1):172-85. DOI: 10.1016/s0304-4165(99)00177-4. View

15.

Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner J . Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol. 2005; 132(1):51-6. DOI: 10.1007/s00432-005-0040-1. View

16.

Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S . Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000; 6(4):1389-93. View

17.

Kasai K, Hirabayashi J . Galectins: a family of animal lectins that decipher glycocodes. J Biochem. 1996; 119(1):1-8. DOI: 10.1093/oxfordjournals.jbchem.a021192. View

18.

Iacovazzi P, Notarnicola M, Caruso M, Guerra V, Frisullo S, Altomare D . Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol. 2009; 32(1):160-4. DOI: 10.1080/08923970902936880. View

19.

Ellerhorst J, Troncoso P, Xu X, Lee J, Lotan R . Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res. 1999; 27(5):362-7. DOI: 10.1007/s002400050164. View

20.

Berberat P, Friess H, Wang L, Zhu Z, Bley T, Frigeri L . Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem. 2001; 49(4):539-49. DOI: 10.1177/002215540104900414. View